Bioversys AG (SW:BIOV) — Stock Price
Bioversys AG (SW:BIOV) is currently trading at CHF27.50 CHF, up 0.00% today. Over the past 52 weeks, shares have ranged between CHF21.50 and CHF33.00. This page tracks Bioversys AG's live share price on the SW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of Bioversys AG.
Bioversys AG (BIOV) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Bioversys AG's daily closing share price and trading volume on the SW exchange over the past year, giving a clear view of recent price momentum and liquidity.
Bioversys AG Income Statement — Revenue, Profit & Earnings by Year
Bioversys AG's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Total Revenue | CHF800.00K | CHF0.00 |
| Cost of Revenue | CHF3.89 Million | CHF3.95 Million |
| Gross Profit | CHF-3.09 Million | CHF-3.95 Million |
| Research & Development | CHF16.50 Million | CHF12.95 Million |
| SG&A | — | — |
| Total Operating Expenses | CHF20.76 Million | CHF18.72 Million |
| Operating Income | CHF-19.96 Million | CHF-18.72 Million |
| EBITDA | — | — |
| EBIT | — | — |
| Interest Expense | CHF1.08 Million | CHF1.04 Million |
| Income Before Tax | CHF-21.81 Million | CHF-18.72 Million |
| Income Tax Expense | — | — |
| Net Income | CHF-21.83 Million | CHF-18.72 Million |
Bioversys AG Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Bioversys AG's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Total Assets | CHF90.64 Million | CHF34.96 Million |
| Total Current Assets | CHF89.87 Million | CHF34.40 Million |
| Cash & Equivalents | — | — |
| Short-term Investments | — | CHF6.00 Million |
| Net Receivables | — | — |
| Inventory | — | — |
| Property, Plant & Equipment | — | — |
| Goodwill | — | — |
| Total Liabilities | CHF30.82 Million | CHF24.27 Million |
| Total Current Liabilities | CHF8.90 Million | CHF9.67 Million |
| Long-term Debt | CHF21.28 Million | CHF13.63 Million |
| Net Debt | — | — |
| Total Stockholder Equity | CHF59.81 Million | CHF10.68 Million |
| Retained Earnings | CHF-101.13 Million | CHF-80.34 Million |
Bioversys AG Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Bioversys AG generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Operating Cash Flow | CHF-21.95 Million | CHF-15.57 Million |
| Capital Expenditures | CHF216.00K | CHF38.00K |
| Free Cash Flow | CHF-22.16 Million | CHF-15.61 Million |
| Investing Cash Flow | — | — |
| Financing Cash Flow | — | — |
| Dividends Paid | — | — |
| Stock-Based Compensation | CHF663.00K | CHF1.86 Million |
| Depreciation | CHF297.00K | CHF282.00K |
| Change in Cash | CHF56.41 Million | CHF1.58 Million |
Bioversys AG Earnings History — EPS Actual vs. Analyst Estimates
Track Bioversys AG's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 01, 2026 | 0.00 | -1.07 | +100.00% |
| Dec 31, 2025 | — | -1.07 | — |
| Dec 03, 2025 | -0.99 | -0.99 | +0.00% |
| Sep 10, 2025 | -2.05 | 0.00 | — |